INTRODUCTION
Hereditary spastic paraplegias (HSPs) are a heterogeneous group of rare inherited disorders characterized by pyramidal syndrome either occurring alone (pure forms) or associated with other neurological or extra neurological signs (complex forms) (Fink, 2013) . The estimated prevalence of HSP is one to 10 out of 100,000 depending on the geographical area (Ruano, Melo, Silva, & Coutinho, 2014) .
HSPs are transmitted according to all modes of inheritance and more than 70 loci have been identified thus far (Tesson, Koht, & Stevanin, 2015) . Genetic studies in HSPs have pointed up key cell functions and have shed light on the molecular mechanisms vital for maintaining neuronal homeostasis (Fink, 2013) . Among the molecular and cellular pathways altered in HSP, a subset is caused by damages in phospholipids, sphingolipids, and fatty acids metabolism (e.g., B4GALNT1/SPG26, DDHD1/SPG28, FA2H/SPG35, NTE/SPG39, GBA2/SPG46, DDHD2/SPG54, and CYP2U1/SPG56) (Lamari, Mochel, & Saudubray, 2015) . SPG56 (termed SPG49 according to the HUGO nomenclature, MIM# 615030) is a rare autosomal recessive early onset complex form of HSP due to mutations in CYP2U1 (MIM# 610670), encoding a member of the cytochrome P450 family 2 (Tesson et al., 2012) .
Few studies are presently available on this "orphan" enzyme predominantly expressed in brain and thymus with a bimodal targeting to endoplasmic reticulum and mitochondria (Chuang et al., 2004; Dhers, Ducassou, Boucher, & Mansuy, 2017a; Guengerich, 2015; Karlgren et al., 2004; Tesson et al., 2012) . CYP2U1 is known to hydroxylate arachidonic acid (AA) into two bioactive metabolites , and other longchain fatty acids (Chuang et al., 2004) . It was recently reported to also catalyze the hydroxylation of N-arachidonoylserotonin (AS), an inhibitor of fatty acid amide hydrolase, into 2-oxo-AS (Siller et al., 2014) . However, there are few data available on CYP2U1 physiological functions (Dhers et al., 2017a) .
To date, 11 families have been reported having variants in CYP2U1 (Citterio et al., 2014; Iodice et al., 2017; Kariminejad et al., 2016; Kumar et al., 2016; Leonardi et al., 2016; Masciullo et al., 2016; Tesson et al., 2012) . Among them, truncating and missense variants have been observed either at homozygous or compound heterozygous state. The functional consequences of missense variants are difficult to interpret only on the basis of bioinformatics predictions, and most are referred to as "variant of uncertain/unclassified significance" (VUS) (Plon et al., 2008) . The extent of high-throughput techniques including next-generation sequencing (NGS) in clinical settings have led to identify a growing number of VUS whose pathogenicity require functional confirmation of disease relationships. This is particularly true for CYP2U1/SPG56 variants for which no biomarker and no study of enzymatic activity are presently available.
In this report, we describe two further SPG56 families in which patients carry either homozygous or compound heterozygous missense variants. To assess the functional consequences of CYP2U1/SPG56 missense variations, we have developed an in vitro assay to compare spectroscopic, relative enzymatic activity, and structural characteristics of the wild-type and mutated proteins. Combining studies of new variants together with those already observed in SPG56 patients, we found that most, but not all, of the missense variants lead to an inhibition of enzymatic activity that can be explained by the loss of proper heme binding to the protein or modification in protein structure.
MATERIALS AND METHODS

Selection of patients and genetic analyses
We selected 444 unrelated index cases with HSP compatible with an autosomal recessive inheritance. Patients were assessed through routine diagnosis procedures in the SPATAX research network (https://spatax.wordpress.com/downloads/). Blood samples were collected with signed informed consent according to the ethical guidelines of the participating institutions; this study was approved by the Paris Necker ethics committee (to AD). Whole genomic DNA was extracted through standard phenol-chloroform-or salting out-dependent procedures followed by ethanol precipitation and resuspension in Tris-EDTA buffer.
Sanger sequencing of coding exons and intron-exon boundaries of CYP2U1 (GenBank reference sequences NM_183075.2 and NG_007961.1) and search for genomic rearrangements by quantitative multiplex PCR of short fluorescent fragments (QMPSF) were carried out to identify causative variants as described elsewhere (Tesson et al., 2012) . Alternatively, we used a customized target re-sequencing panel able to investigate the coding regions of all known genes linked to spastic ataxias or paraplegias. Pathogenicity prediction was performed using Sift (https://sift.bii.a-star.edu.sg/; (Ng & Henikoff, 2003) ), MutationTaster (https://www.mutationtaster.org/; (Schwarz, Cooper, Schuelke, & Seelow, 2014) ), Polyphen-2 (https://genetics.bwh.harvard.edu/pph2/; (Adzhubei, Jordan, & Sunyaev, 2013) ), and MutaCYP (https://research.cchmc.org/MutaSense/; (Fechter & Porollo, 2014) 
Incubation conditions, metabolite extraction
HPLC and MS analysis
HPLC-MS/MS (MRM mode) analyses were performed with a QTRAP R 5500 (ABSciex, Redwood City, CA) mass spectrometer coupled to an HPLC system (Ultimate 3000; Dionex, Sunnyvale, CA).
Analyses were achieved in the negative mode. Nitrogen was used for the curtain gas (set to 20), gas1 (set to 20), and gas2 (set to 10). Needle voltage was set at −4,500 V without needle heating; the declustering potential was set at −50 V and collision energy at −30 eV for AA and AA-d8 and −25 eV for 19-, 20-HETE, and 5-HETEd8. The collision gas was also nitrogen. The dwell time was set to 3 msec. Figure S2A and B) (Chuang et al., 2004) . The formation of the two metabolites was observed with retention time of 2.82 (19-HETE) and 3.00 (20-HETE) min upon incubation of CYP2U1 WT with AA (Suppl. Figure S2C ). The relative amounts of 19-and 20-HETE were obtained using 5-HETEd8
as internal standard, and normalized to the amount of CYP2U1 protein determined by Western blot.
Spectroscopic study of CYP2U1 wild-type and variants
All UV-visible spectra were collected at room temperature using a Kontron Uvikon 941 dual-beam spectrophotometer with a 1 cm-path length (120 l) quartz cuvette. In a typical experiment, spectra were recorded in the differential mode (380-500 nm) after addition of 110 l of the lysate from transfected HEK293T cells and of 10 l of a saturated solution of sodium dithionite in both cuvettes, recording of a baseline, and bubbling of CO in the sample cuvette. The concentrations of the P450 FeII-CO complex were calculated using an value of 91,000 M −1 cm −1 for ΔDO(450-480 nm) (Omura & Sato, 1962 ).
Molecular modeling
All computations were performed on a Dell Precision Workstation connected to the Computing Center for Research and Technology (CCRT, Bruyère-le-Châtel, France). A 3D model of CYP2U1 deprived of its membrane spanning domain (residues 57-544) was built using
Modeller9v8 (Sali, Potterton, Yuan, van Vlijmen, & Karplus, 1995) and the crystal structures of CYP2D6 (PDB 2F9Q), CYP2R1 (PDB 3CZH), CYP2A6 (PDB 1Z10), CYP2C5 (PDB 1DT6), CYP2B4 (PDB 1PO5), and CYP2C8 (PDB 1PQ2) were used as templates, as previously described (Dhers et al., 2017b; Ducassou et al., 2015) . Molecular docking experiments of AA at the active site were performed using either AutoDock 4.2 in the flexible mode (Goodsell, Morris, & Olson, 1996; Morris et al., 2009) or CDOCKER (Wu, Robertson, Brooks, & Vieth, 2003) with Discovery Studio 4.1 (Accelrys, Dassault Systems Biovia), as previously described (Dhers et al., 2017b; Ducassou et al., 2015) . Using our 3D model, the possible effects of variants on CYP2U1 structure were investigated using virtual mutagenesis (Swiss Model). Mutant models were generated using Built Mutant protocol from Discovery Studio 4.1.
A set of 100 structures was created and ranked for their Dope score.
The best model was then minimized using Adopted Basis NewtonRaphson algorithm (a Newton-Raphson algorithm applied to a subspace of the coordinate vector spanned by the displacement coordinates of the last positions) until a RMS gradient of 0.001 was obtained.
The putative effects of mutants on protein stability and heme binding were evaluated using both Fold-X program and Discovery Studio 4.1 algorithms: Calculated Mutant Energy (folding) for protein folding, and Calculated Mutant Energy (binding) for heme stability with standard settings. The PyMOL Molecular Graphics System, Version 1.4 was used for structure rendering.
RESULTS
Genetic findings
To date, five homozygous truncating variants, three homozygous missense variants, and six missense or truncating variants in compound heterozygosity have been observed in CYP2U1 gene from SPG56 patients (Table 1 and Figure 1 ). In this report, our genetic screening identified two novel SPG56 families carrying three novel CYP2U1 . Table S1 ). Through this screening, we also found monoallelic variants of uncertain bioinformatics significance in seven unrelated patients (Supp. Note 1 and Supp. Table S1 ).
Clinical reports of novel cases
Patient 1 was a boy born from consanguineous parents (Suppl. Figure   S1A ) of Turkish origin. At the age of 2 years, he displayed lower limbs (LL) spastic paraplegia very rapidly worsening and associated with a mild intellectual disability (ID). Neurological examination at the age of 12 years showed marked spasticity in the LL associated with signs of peripheral neuropathy such as decreased reflexes, distal wasting, and cold feet. There were no cerebellar signs. Brain MRI showed hyperintensities in the posterior periventricular white matter on T2 and FLAIR images and mild atrophy of the corpus callosum. The patient was tested negative for mutations in the SPG11 gene and carries a heterozygous frameshift mutation in SPG7 that may have contributed to the rapid disease worsening.
Patient 2 was a boy born from unrelated Italian parents with family history of undefined neuromuscular disorder and ID in maternal relatives (Supp. Figure S1B ). The patient presented LL spasticity since the age of 14 months. Brain MRI at the age of 18 months showed periventricular hyperintensities of cerebral white matter suggesting incomplete myelination associated with discrete widening of bilateral CSF spaces. The boy could walk unaided at the age of 2 years only on a short distance. At the age of 4 years, neurological examination presented LL spasticity with no evidence of cerebellar involvement.
The Wechsler Intelligence Scale for Children (WISC-IV) scores were in the normal range although there were difficulties in language skills and learning abilities. A detailed description of this patient is provided in supplementary information. No pathological variant was found in SPAST, ATL1, REEP1, or GLUT1 genes.
Pathogenicity classification of CYP2U1 variants
Up to now, 17 variants have been reported in SPG56 families (Table 1 and Figure 1 ) including those described in this work (Citterio et al., 2014; Iodice et al., 2017; Kariminejad et al., 2016; Kumar et al., 2016; Leonardi et al., 2016; Masciullo et al., 2016; Tesson et al., 2012) .
Nine of them predict protein truncation and are therefore classified as deleterious according to sequence variant classification and interpretation guidelines (VUS class 5) (Plon et al., 2008; Richards et al., 2015) . In silico predictions using different bioinformatic tools were performed for each missense variant using Polyphen-2, Mutation taster, SIFT, and MutaCYP (Table 1 and Supp. Table S1 ). The 
Expression in HEK293T cells and characterization of CYP2U1 and its variants
Expression vector pCS 2+ containing human wild-type or mutated CYP2U1 cDNA was transiently overexpressed in HEK293T cells.
In this article, we focused our functional analyses on constructs carrying class 3 and 4 VUS, namely p.Cys262Arg, p.Asp316Val, p.Glu380Gly, and p.Arg488Trp variants previously described in SGP56 families by our group (Tesson et al., 2012) , and the p.Gly115Ser, Fluorescence ratio of CYP2U1/actin was measured for each condition. The ratio is normalized to CYP2U1 WT and is represented as the mean ± SEM. AU, arbitrary unit. The statistical significance of the results was analyzed using one-way ANOVA, multiple-comparison test. ****P < 0.001; ***P < 0.001; **P < 0.01; ns, not significant recognized by an anti-CYP2U1 antibody (Figure 2A ). Otherwise, a similar Western blot analysis of the lysate of HEK293T cells transfected with the empty plasmid showed a faint band of the same molecular mass corresponding to the endogenous CYP2U1 protein. Most constructs (CYP2U1 G115S , CYP2U1 C262R , CYP2U1 E380G , CYP2U1 R384I , and CYP2U1 C490Y ) had similar levels of protein expression and produced proteins of similar size as CYP2U1 WT (Figure 2A ).
The CYP2U1 R390* construct led to a truncated protein of approximately 35 kDa. We observed that the CYP2U1 R488W (66 ± 8%) and CYP2U1 R390* (54 ± 8%) constructs showed a slightly, however significantly reduced level of expression compared with CYP2U1 WT (**P < 0.01 and ***P < 0.001, respectively; Figure 2B ). By contrast, extremely low expression levels was found for the CYP2U1 D316V
protein (5 ± 2%; ****P < 0.0001). These results were confirmed with a second specific antibody (data not shown).
As expected (Karlgren et al., 2004) , the UV-vis difference spectrum of lysate from HEK293T cells expressing CYP2U1 WT showed a peak at 450 nm characteristic of the presence of a cytochrome P450 Fe II -CO complex ( Figure 3A) . The presence of such a 450 nm absorbing complex was also found with the CYP2U1 E380G and CYP2U1 R384I variants (85 ± 10% and 95 ± 15%, respectively, compared with CYP2U1 WT ; Figure 3B ). By contrast, this characteristic difference spectrum could not be detected in the lysates of HEK293T cells overexpressing the CYP2U1 G115S , CYP2U1 C262R , CYP2U1 D316V CYP2U1 R488W , and CYP2U1 C490Y variants ( Figure 3B ). 
AA oxidation by CYP2U1 WT
It has been previously shown that CYP2U1 expressed in baculovirusinfected Sf9 insect cells or in Escherichia coli was able to catalyze theand -1 hydroxylations of AA (Chuang et al., 2004; Siller et al., 2014) . 
Arachidonic oxidation by CYP2U1 variants
The CYP2U1 E380G and CYP2U1 R384I variants displayed an activity similar to that of CYP2U1 WT ( Figure 3C and Supp. Figure S2D ). At 5 M AA, those two variants reached the wild-type enzyme maximum activity (99 ± 8% and 101 ± 25% for 20-HETE production and 99 ± 10% and 96 ± 30% for 19-HETE production; Figure 3C and D). In contrast, no 19 and 20-HETE formation could be detected when CYP2U1 G115S , CYP2U1 D316V , CYP2U1 C490Y , CYP2U1 R488W , and CYP2U1 C262R lysates were incubated with AA, suggesting a complete loss of enzymatic activity, as is the case for the truncating mutation CYP2U1 R390* ( Figure 3C and D). As a very low level of protein expression was observed for CYP2U1 D316V , we incubated higher concentrations of lysate proteins but yet did not observe quantifiable amounts of metabolites suggesting that the residual mutated protein was not active (data not shown).
Molecular modeling studies
To further understand the functional impact and the pathogenic effect of the missense variants identified in SPG56 patients and determine if the effects observed at the enzymatic level could be explained by their F I G U R E 4 3D-Model of the CYP2U1-AA complex, and location of the mutated residues in the missense variants studied in this paper. Right view is deduced from left view by a 90 • rotation around an axis perpendicular to the heme. Heme is in orange and AA in violet. Helixes F, G, and I are shown in black, green, and yellow, respectively. The BC-loop is shown in blue. The carbon atoms of mutated residues are indicated by red balls, the oxygen atoms by blue balls, and the sulfur atoms by yellow balls location in the protein, we used our recently published 3D CYP2U1 model (Ducassou et al., 2015) (Figure 4) . Docking studies showed AA in a completely extended conformation, stretching through channel 2ac all the way to the protein surface and interacting through its carboxylate group with positively charged residues of the protein such as amino acid Lys292 at the entry of this channel (Figure 4 ) (Ducassou et al., 2015) .
The Cys490 residue of CYP2U1 is the highly conserved cysteine acting as iron axial ligand. Arg488 is present in most human P450s (48 of the 57 human P450s) and is involved in the binding of one of the heme propionate residues (Dhers et al., 2017a) . The inability of the p.Cys490Tyr and p.Arg488Trp variants to bind heme correctly might explain the loss of enzyme activity observed experimentally for AAand -1 hydroxylation ( Figure 3D ) and the absence of the 450 nm peak that is characteristic of cytochrome P450s in UV-vis difference spectroscopy.
The Asp316 residue is located at the end of the GH loop and strongly interacts with positively charged residues on helix G, such as His305, within an H-bond network ( Figure 5A ). Construction of a 3D model of the p.Asp316Val variant followed by a 20 ns molecular dynamics simulation showed that disruption of this H-bond network by changing Asp for Val at this position appeared to greatly affect the protein conformation. This resulted in a curving of helix G and a movement of helix H that becomes more exposed to solvent ( Figure 5B ). Such dramatic changes in the protein conformation might affect its stability and favor its proteolytic cleavage that could explain the much lower protein expression observed by Western blot (Figure 2 ).
The Gly115 residue is located at the junction of helix A and -1 sheet ( Figure 5C ), after the transmembrane helix (TMH). This residue is highly conserved in the 57 human CYPs, except for those of family 4 (Dhers et al., 2017a) . Its replacement with a bulkier residue, as in the p.Gly115Ser variant, should lead to a steric clash between the side chain of this residue and that of the Pro61 residue located at the TMH end, as shown in a 3D model of CYP2U1 including this helix ( Figure 5D ).
Such steric clash that should occur in the p.Gly115Ser could destabilize the CYP2U1 protein and lead to a complete loss-of-function, explaining the lack of 450 nm peak in the UV-vis difference spectrum of this protein and its inability to hydroxylate AA.
The Cys262 residue is located in the end of helix F, in the roof of the AA binding site just above the heme plane ( Figure 5E ). The Arg262 residue could bind to a heme propionate and lead to an incorrect binding of the heme in the active site ( Figure 5F ). This would explain the absence of a 450 nm peak in the UV-vis difference spectrum of this protein and its inability to hydroxylate AA.
Finally, the Glu380 and Arg384 residues are located in helix J, relatively far from the active site (Figure 4) . Moreover, the corresponding side chains of these amino acids point toward the exterior of the protein. Their replacement with Gly and Ile residues, respectively, should not affect the stability of the protein and the structure of its active site, explaining minor changes in protein expression, 450 nm-absorbing spectrum, and AA hydroxylation activities.
DISCUSSION
In the present study, we identified two novel unrelated patients carrying homozygous and compound heterozygous variants in CYP2U1/SPG56. Both patients manifested typical early onset complex HSP with severe functional impairment associated with ID and brain MRI abnormalities suggestive of white matter changes and initially interpreted as delayed myelination due to perinatal insults. The clinical spectrum of SPG56 is wide and pure and complex forms of HSP have been described (Citterio et al., 2014; Iodice et al., 2017; Kariminejad et al., 2016; Kumar et al., 2016; Leonardi et al., 2016; Masciullo et al., 2016; Tesson et al., 2012) . Cognitive impairment, brain MRI abnormalities, dystonia, and peripheral neuropathy are among the most frequently associated features in complex forms, including SPG56 (Kariminejad et al., 2016) .
The recent advances in molecular genetics have revealed the underestimated clinico-genetic heterogeneity of HSP, including their clinical and genetic overlap with other diseases (Tesson et al., 2015) . In views C and D, helix A and 1 sheet are shown in yellow and blue, respectively; heme is in yellow, and part of TMH in gray. In views E and F, helixes G and I are shown in green and yellow, respectively; BC loop is blue. In wild-type CYP2U1 (E), AA is shown in violet, Lys292 in blue and heme in yellow. View F (p.Cys262Arg variant) shows the putative positioning of side chain of residue Arg262 (blue balls) that could bind to a heme propionate (yellow, with O-atoms red) and lead to an incorrect binding of the heme in the active site increasing number of unsolved cases carrying variants with very limited pathogenicity predictions due to limitations of in silico tools and our current state of knowledge. Thus, there is a striking need of validation tests with functional studies.
In this study, we have set up an enzymatic assay for wild-type and mutated CYP2U1 and used a 3D model of the encoded enzyme to interpret the functional consequences of missense variants identified in SPG56 cases. We focused our analysis on seven missense variants and their expression levels, ability to exist as cytochrome P450s, and enzymatic activity toward AA hydroxylation. P450s and were associated in fact with a normal enzyme activity.
Thus, the five variants (p.Gly115Ser, p.Cys262Arg, p.Arg316Val, p.Arg488Trp, and p.Cys490Tyr) described in SPG56 patients leading to functionally inactive enzyme toward AA hydroxylation can be then considered as disease-causing variants and thus reclassified as VUS Class 5. Conversely p.Glu380Gly variant previously reported as disease associated (Tesson et al., 2012) and the p.Arg384Ile variant reported here, appear to be neutral at least in our experimental system testing AA hydroxylation. Additionally, the p.Arg384Ile variant is present in various databases, including at homozygous state and was found in cis with p.Gly115Ser on the paternal allele in patient 2, and at heterozygous state in two additional patients. Thus, it can be assumed that those variants (p.Glu380Gly and p.Arg384Ile) are benign and can be reclassified as VUS Class 1. Taken together, these results strongly confirm the ability of our in vitro assay to explore the functional significance and corroborate pathogenicity of future variants identified in
CYP2U1.
We have shown that several CYP2U1 function affecting variants observed in SPG56 patients had a strong effect on AA hydroxylation affecting 19-and 20-HETE production. Besides their structural function, complex lipids are also linked to important physiological processes such as bioenergetics, cell recognition, or signal transduction and are involved in communication and signalling between cells (Lamari et al., 2015) . CYP2U1 is expressed in cerebellum with abundant transcripts in astrocytes suggesting an important role of AA metabolism pathway in brain (Dutheil et al., 2009) . 20-HETE generated from the AA hydroxylation is a potent vasoconstrictor that is implicated in the regulation of cerebral blood flow and in the coupling of regional brain blood flow to neuronal activity (Imig, Simpkins, Renic, & Harder, 2011) . Increased production of 20-HETE has been associated with ischemic stroke and hemorrhagic cerebral vasospasm (Poloyac, Reynolds, Yonas, & Kerr, 2005) . Recent studies have shown that 20-HETE can be released by astrocytes and produces vasoconstriction of cerebral blood vessel (Gebremedhin et al., 2016) . Astrocytes are the main population of glial cells in the central nervous system that play a crucial role in the maintenance of the blood-brain barrier, nutrient supply of neurons, neurotransmitter recycling, and regulation of blood circulation. Recent evidence suggests that vascular abnormality leads to neuronal dysfunction and neurodegeneration (Zlokovic, 2011) . Thus, mutations in CYP2U1 causing an inhibition of 20-HETE production by astrocytes could affect neuronal homeostasis resulting in the neurodegeneration observed in SPG56 patients. The neuron-glial collaboration is essential to the development and maintenance of the neural network and could therefore be affected by deficits in 20-HETE production from AA hydroxylation due to mutation in CYP2U1.
Although the number of mutations identified in HSP genes involved in lipid metabolism is growing, our knowledge of their pathophysiological consequences remains limited. Studies correlating potential deleterious variants and their consequences in terms of biological effects should pave the way to a better understanding of biological functions in the brain as well as open the way to identify the best targets for therapeutics.
